SET/TAF-I Antikörper (AA 175-225)
Kurzübersicht für SET/TAF-I Antikörper (AA 175-225) (ABIN1933982)
Target
Alle SET/TAF-I (SET) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 175-225
-
Spezifität
- Region between residue 175 and 225 of human SET nuclear oncogene using the numbering given in entry NP_001116293.1 (GeneID 6418).
-
Aufreinigung
- Immunoaffinity purified
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
-
Approved: IF (1:100 - 1:500), IHC, IHC-P (1:200 - 1:1000), IP (3 - 5 μg/mg lysate), WB (1:2000 - 1:10000)
Usage: Immunohistochemistry: Antigen retrieval with citrate buffer pH 6.0 is recommended for FFPE tissue sections. Human controls: Breast Carcinoma, Colon Carcinoma, Ovarian Carcinoma, Prostate Carcinoma. -
Kommentare
-
Target Species of Antibody: Human
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- Lot specific
-
Buffer
- Tris-buffered saline, 0.1 % BSA, 0.09 % sodium azide.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C
-
Informationen zur Lagerung
- Store at 2-8°C for up to 1 year.
-
Haltbarkeit
- 12 months
-
-
- SET/TAF-I (SET) (SET Nuclear Oncogene (SET))
-
Andere Bezeichnung
- SET / TAF-I
-
Hintergrund
-
Name/Gene ID: SET
Synonyms: SET, 2PP2A, HLA-DR-associated protein II, I-2PP2A, TAF-IBETA, SET nuclear oncogene, TAF-I, Template-activating factor I, I2PP2A, IGAAD, IPP2A2, PHAPII, Protein SET -
Gen-ID
- 6418
-
Pathways
- Apoptose
Target
-